arrow_back
Medical Information
  • GILEAD and the GILEAD logo are trademarks of Gilead Sciences, Inc. KITE and the KITE logo are trademarks of Kite Pharma, Inc. © 2024 Gilead Sciences, Inc. All rights reserved. IHQ-UNB-5659 May 2024

Cell therapy research.

Cell therapy is a unique therapeutic platform where a patient's own cells are the starting point to create the treatment. Cell therapy modifies a patient's own immune cells to target their cancer.

Research commitment
Clinical trials in progress
Scientific focus

Committed to patients living with blood cancers

Select a trial below to view additional details (trial brochure or clinicaltrials.gov)
Timeline is based on clinical trial start date.


The safety and efficacy of these investigational agents or investigational uses of marketed products have not been established. These uses have not been approved by regulatory authorities. There is no guarantee that these therapies or uses will be commercialized.

2016
ZUMA-4a,*

Pediatric R/R ALL/NHL

2021
KITE-363*
CD19/20 BICISTRONIC

R/R DLBCL

 
KITE-753b,*
CD19/20 BICISTRONIC

R/R DLBCL

2022
ZUMA-22*

2L+ high-risk FL

 
ZUMA-24*

2L+ LBCL outpatient

 
iMMagine-1c,*

2L+ R/R MM

2023
ZUMA-23

1L high-risk LBCL

 
KITE-197b,*
Next-gen CD19 CAR-T

R/R DLBCL

2024
iMMagine-3*

R/R MM

00

Clinical trials in progress

Cell therapy clinical trials actively recruiting.

Rollover trial for links to trial brochures and/or clinicaltrials.gov records.

The safety and efficacy of these investigational agents or investigational uses of marketed products have not been established. These uses have not been approved by regulatory authorities. There is no guarantee that these therapies or uses will be commercialized.

R/R LBCL
Phase 1 open-label, multicenter study evaluating the safety and efficacy of KITE-363 or KITE-753, autologous anti-CD19/CD20 CAR T-cell therapies, in subjects with R/R LBCL
LBCL

KITE-363 or KITE-753

R/R MM
A Phase 2 open label, multicenter, study of antiocabtagene autoleucel for the treatment of patients with relapsed or refractory multiple myeloma
MM

iMMagine-1a

2L+ high-risk FL
Phase 3 randomized, open-label, multicenter study evaluating the efficacy of axicabtagene ciloleucel versus standard of care therapy in patients with R/R FL
FL

ZUMA-22

1L high-risk LBCL
Adaptive Phase 3, randomized, open-label, multicenter study to compare the efficacy and safety of axicabtagene ciloleucel versus standard of care therapy as first-line therapy in subjects with high-risk LBCL
LBCL

ZUMA-23

2L LBCL outpatient
Phase 2 open-label, multicenter study evaluating the safety and efficacy of axicabtagene ciloleucel concomitant with prophylactic steroids in patients with R/R LBCL in the outpatient setting
LBCL

ZUMA-24

Scientific focus

The safety and efficacy of these investigational agents or investigational uses of marketed products have not been established. These uses have not been approved by regulatory authorities. There is no guarantee that these therapies or uses will be commercialized.
Scientific focus
The D-Domain
CAR T cell therapy
Cell therapy manufacturing

Clinicaltrials.gov may not reflect the most up-to-date information on the trials shown.

*Ongoing trials

aTrial status: active, not recruiting. bManufacturing innovation. cIn collaboration with Arcellx.

1l, first line; 2L, second line; ALL, acute lymphoblastic leukemia; AML, acute myeloid leukemia; DLBCL, diffuse large b-cell lymphoma; FL, follicular lymphoma LBCL, large b-cell lymphoma; MM, multiple myeloma; NHL, non-Hodgkin lymphoma; R/R, relapsed/refractory.

1. Gilead Sciences Inc. Third Quarter 2023 Resource Book. November 7, 2023. Available at: https://s29.q4cdn.com/585078350/files/doc_financials/2023/q3/GILD-Q323-Resource-Book-7-November-2023.pdf